

Parkinson's: Switching To Orodispersible Formulations In The Dying Patient

Medication	Formulation	Recommendation
<p>Co-beneldopa (contains benserazide and levodopa)</p> <p>Brand: Madopar®</p>	<p>Dispersible Madopar® tablets</p>	<p>Continue – no change required. Tablets disperse in 10 ml of water within 2 minutes to give a cloudy white dispersion.</p>
	<p>Capsule</p>	<p>Convert to dispersible Madopar® tablets.</p>
	<p>Modified release tablets – Madopar CR®</p>	<p>Convert to dispersible Madopar® tablets and reduce dose by about 30%, for example:</p> <ul style="list-style-type: none"> • 50/200mg CR converts to 1 tablet 25/100mg + 1 tablet 12.5/50mg • 25/100mg CR to 1 tablet 12.5/50mg
<p>Co-careldopa (contains carbidopa and levodopa)</p> <p>Brands include: Sinemet® and Caramet®</p>	<p>Tablets (standard release) – includes Sinemet Plus®</p>	<p>Continue – no change required as tablets will disperse in water.</p> <p>Tablets disperse in 10 ml of water within 2 minutes to form a bright yellow dispersion.</p> <p>Care must be taken to administer whole dose owing to the tendency for settlement to the bottom of the container / syringe.</p>
	<p>Controlled release tablets – e.g. Half Sinemet CR® and Sinemet CR®</p>	<p>Convert to dispersible Madopar® tablets and reduce dose by about 30%, for example:</p> <ul style="list-style-type: none"> • 50/200mg CR converts to 1 tablet 25/100mg + 1 tablet 12.5/50mg • 25/100mg CR to 1 tablet 12.5/50mg

Medication	Formulation	Recommendation
<p>Entacapone</p>	<p>Tablets (standard release)</p>	<p>Unlikely any meaningful impact - consider stopping.</p> <p>Difficult to disperse and has a bitter taste.</p>
<p>Opicapone Brand: Ongentys®</p>	<p>Capsule</p>	<p>Unlikely any meaningful impact - consider stopping.</p> <p>No information available on crushing from Manufacturer and difficult to disperse.</p>
<p>Levodopa/Carbidopa/Entacapone Brands include: Stalevo®, Sastravi®, Stanek®</p>	<p>Tablets (standard release)</p>	<p>Switch to Co-careldopa or Sinemet® and entacapone – the latter can be omitted.</p>
<p>Pramipexole Brands include: Mirapexin® and Pipexus®</p>	<p>Tablets (standard release)</p>	<p>Continue current regimen, tablets will disperse in 10mL of water.</p>
	<p>Modified release tablets</p>	<p>Convert to standard release and change total daily dose to TDS regimen.</p>
<p>Ropinirole Brands include: Requip®, Adarte®</p>	<p>Tablets (standard release)</p>	<p>Continue current regimen. Tablets will disperse in 10mL of water to give fine dispersion.</p>
	<p>Modified release tablets</p>	<p>Convert to standard release and change total daily dose to TDS regimen.</p>
<p>Rasagiline Brand: Azilect®</p>	<p>Tablets (standard release) *oral suspension or solution are only available by special order from manufacturer</p>	<p>Unlikely any meaningful impact - consider stopping.</p> <p>If wish to continue, tablets can be crushed and mixed in water.</p>

Medication	Formulation	Recommendation
<p>Selegiline</p> <p>Brands include: Eldepryl® and Zelapar®</p>	<p>Tablets (standard release)</p>	<p>Unlikely any meaningful impact - consider stopping.</p> <p>If wish to continue, tablets will disperse in water.</p>
	<p>Oro-dispersible tablets <u>Note:</u> 1.25mg = 10mg standard release tablet</p>	<p>Unlikely any meaningful impact - consider stopping.</p> <p>No change if oral route is safe.</p>
<p>Amantadine</p>	<p>Capsule</p>	<p>May contribute to agitation in the dying patient. Consider stopping.</p> <p>If strong desire to continue, capsules can be opened and dissolved in water, or a liquid formulation can be prescribed.</p>
<p>Safinamide</p> <p>Brand: Xadago®</p>	<p>Tablet</p>	<p>Unlikely any meaningful impact - consider stopping</p> <p>No information available on crushing from Manufacturer.</p>

[See References 1,2,6,7,13,14 on our website](#)